Rare disease biotech Edgewise Therapeutics files for a $100 million IPO

Edgewise Therapeutics, a Phase 1 biotech developing small molecule therapies for rare muscle disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

Edgewise is focused on the discovery, development, and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its lead candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies. It is currently in a Phase 1 trial for Duchenne muscular dystrophy, Becker muscular dystrophy, and Limb-girdle muscular dystrophy.

The Boulder, CO-based company was founded in 2017 and plans to list on the Nasdaq under the symbol EWTX. Edgewise Therapeutics filed confidentially on December 18, 2020. J.P. Morgan, Goldman Sachs and SVB Leerink are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Rare disease biotech Edgewise Therapeutics files for a $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.